ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scientific Advisory Board
Retrieved on:
Tuesday, December 12, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Biophysics, NIAID, TCR, Organization, Allen Institute, Executive Committee, National Cancer Institute, Cell Reports, University, Chan Zuckerberg Initiative, Master of Mathematics, Multimedia, Computational biology, Systems biology, Biomedicine, Allele, SAB, Machine learning, HLA, COVID-19, Kidney, Therapy, Intramural sports, NIH, World Allergy Organization, Cancer, Bangladesh Technical Education Board, CHI, Harvard University, Biomedical engineering, System, Digestive, Bachelor of Applied Science, Infection, Medical device, Management, Yale University, Columbia
ImmunoScape , a biotechnology company focused on next-generation immunotherapies, today announced the appointment of John Tsang, Ph.D. to its Scientific Advisory Board (SAB).
Key Points:
- ImmunoScape , a biotechnology company focused on next-generation immunotherapies, today announced the appointment of John Tsang, Ph.D. to its Scientific Advisory Board (SAB).
- Dr. Tsang joins a distinguished group of leading scientists in immunology and oncology who help to guide ImmunoScape’s scientific strategy.
- Dr. Tsang was also the Co-Director of the Trans-NIH Center for Human Immunology (CHI) and led its research program in systems human immunology.
- Dr. Tsang has won multiple awards for his research, including several NIH/NIAID Merit Awards recognizing his scientific leadership in systems immunology, COVID-19, and human immunology research.